It's that time again. From 'jolted' Jeb to 'cool' Carly and from 'calm' Carson to 'turmoiling' Trump, for some of the GOP presidential nominee candidates, tonight could be the last hoorah in a campaign that has seen apolitical entrants dominate the mainstream Washington muppets. Moderated by John "I never met a Republican I didn't like" Harwood, we are sure there will be some tension as the "general health of the economy" planned focus may morph into any and everything as the debate pushes beyond two hours. Please watch responsibly...
There are few political hacks in Washington more deserving of everlasting ignominy than retiring speaker John Boehner. So here’s a vehement good riddance to the man who has single-handedly destroyed whatever pathetic semblance of fiscal responsibility that remained in Washington.
Don't think the Status Quo will save you, or make good on its vast multitude of promises. Naive faith in promises and fantasies isn't helpful in the real world.
The signs of regime change are everywhere. From embarrassment by Russia's success in Syria to China's creation of its own 'World Bank' and SWIFT alternative, the trend of de-empirization are growing, but tonight's news that Washington will sell oil from its strategic reserve in order to meet budget constraints and avoid default (as China takes advantage of low prices to build its own reserves) is simply stunning in its analogy of the shifting world order.
If Bernie Sanders really believes that socialism is the solution, then he is misguided – even though his criticism of oligarchic cronyism is justified. Socialists believe that the society is just one “organic body” and as with all such entities resources are used indiscriminately by the organism so as to support its various functions, organs, faculties, etc., never mind who produces and who consumes the resources; those are for the whole system to use as is needed: “From each according to his/her ability, to each according to his/her need!” Trouble is some of the people will have to decide about all this. It is not automatic, contrary to what Marxists think. And here is where the politicians and their appointed bureaucrats enter the picture.
Reality is only what a politician does in office, not about mere rhetoric. Even when rhetoric is great, such as it was with Abraham Lincoln, it has relied upon honesty in order to be able to be so. Lying rhetoric tends simply to be forgotten by historians. It shouldn’t be, even if this requires us to remember some very bad rhetoric. Lies can be very important, no matter how bad the rhetoric might happen to be. History should deal with what’s important. So should voters.
Having become an overnight social and industry outcast, at least Turing Pharma's Martin Shkreli had one thing going for him: a business model that afforded him solid margins, because despite promising to cut the price of the scandalous Daraprim, Turing did not do that. Now, however, even that may be in jeopardy following news that San Diego-based specialty drug maker Imprimis Pharmaceuticals, says it can make a close, customized version of Daraprim for a paltry $1 a pill, NBC reports. That's a big contrast to the $750-a-dose that Shkreli said Turing was going to start charging for the same drug.
Many of the systems we take for granted are historical accidents. Either based on legacy systems hundreds of years old (higher education) or assembled in a short-term, ad hoc fashion (post-1940 national defense/ national security), these systems have expanded into vast patronage systems that are completely out of touch with 21st century needs, costs or realities. The U.S. healthcare system was not planned; it is largely accidental.
- Canada's Trudeau topples PM Harper in shock election win (Reuters)
- Where Canada’s Harper Hit Hurdles (WSJ)
- Pugnacious Trudeau Steps Out of Father's Shadow and Into Power (BBG)
- European Stocks Decline, Euro Rallies as ECB QE Optimism Fades (BBG)
- Valeant, Under Pressure About Price Increases, Plans Changes (WSJ)
- Syrian rebels say they receive more weapons for Aleppo battle (Reuters)
Hillary Clinton Sends Letter To FTC Demanding Review Of Pharma Industry, Turing's "Anticompetitive Practices"Submitted by Tyler Durden on 10/19/2015 09:44 -0500
For those wondering if Hillary Clinton's feud with the pharmaceutical industry in general, and with Turing Pharma's Martin Shkreli in particular, is over we just got the answer: it is only just getting started. Moments ago Reuters reported that Clinton has sent a letter to the FTC for recommendations on "changing laws to prevent anticompetitive practices", with a focus on Turing which has become a poster child for all that is wrong with the US specialty pharma industry, and the pharmaceutical industry in general.
"There are so many fault lines that the nation seems consumed by a conflict of all against all... there is an inevitable “revolution” coming because our politics, culture, education, economics and even philanthropy are so polarized that the country can no longer resolve its differences."
Back on September 28, when the specialty biotech drug scandal was just getting started and leading to a biotech bear market, Valeant stock suddenly plunged $50 leading to massive losses for its top holder Bill Ackman when it was revealed that House democrats had requested a Valeant subpoena. To be sure, the company promptly made it clear that an official subpoena had not actually been sent, just that some politicians were demanding one. That changed overnight when Valeant issued a press release providing an "update regarding government inquiries", in which we learn that the subpoena is now official.
"We simply exhausted the productivity benefits of prior innovations. In the late 19th century, hugely important 'general purpose' technologies, like electricity and the internal combustion engine, were invented."
Despite 'promises' of lower healthcare costs (from President Obama) and 'promises' of a comfortable retirement (if only you invest all your savings in stocks), Bloomberg reports the average 65-year-old couple retiring this year will face health-care costs of $245,000 in the years ahead, up 11% from 2014.
More Pain For Biotechs Ahead: Valeant's "Astronomical" Price Increases Take Center Stage; Pfizer Gets Dragged InSubmitted by Tyler Durden on 10/04/2015 11:44 -0500
Late last week, after looking at Valeant soaring default risk as measured by the price of its blowing out CDS, soaring to over 30% even as its stock prices was surging, we wondered - does someone know something? It appears someone may have known that this weekend, the same Andrew Pollack whose NYT article exposing Turing's 5000% price increase resulted in Hillary Clinton promising to cap specialty biotech prices if elected, has come back for round two and after taking aim at Shkreli and Turing, much to the chagrin of Bill Ackman, Pollack is now taking aim at the biggest culprit: Valeant Pharmaceutcals.